Leighl, N. B., Redman, M. W., Rizvi, N. A., Hirsch, F. R., Mack, P. C., Schwartz, L. H., … Kelly, K. (2020). SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Leighl, Natasha B., Mary Weber Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence Howard Schwartz, James Lloyd Wade, et al. “SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Leighl NB, Redman MW, Rizvi NA, Hirsch FR, Mack PC, Schwartz LH, et al. SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Leighl, Natasha B., et al. “SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Leighl NB, Redman MW, Rizvi NA, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy S, Crawford J, Bradley JD, Stinchcombe T, Ramalingam SS, Miao J, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou V, Kelly K. SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study). JOURNAL OF CLINICAL ONCOLOGY. 2020.